Antibiotics for acute otitis media in children.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
15 11 2023
Historique:
pmc-release: 15 11 2024
medline: 27 11 2023
pubmed: 15 11 2023
entrez: 15 11 2023
Statut: epublish

Résumé

Acute otitis media (AOM) is one of the most common diseases in childhood for which antibiotics are commonly prescribed; a systematic review reported a pooled prevalence of 85.6% in high-income countries. This is an update of a Cochrane Review first published in the Cochrane Library in 1997 and updated in 1999, 2005, 2009, 2013 and 2015. To assess the effects of antibiotics for children with AOM. We searched CENTRAL, MEDLINE, Embase, Current Contents, CINAHL, LILACS and two trial registers. The date of the search was 14 February 2023. We included randomised controlled trials comparing 1) antimicrobial drugs with placebo, and 2) immediate antibiotic treatment with expectant observation (including delayed antibiotic prescribing) in children with AOM. Two review authors independently screened trials for inclusion and extracted data using the standard methodological procedures recommended by Cochrane. Our primary outcomes were: 1) pain at various time points (24 hours, two to three days, four to seven days, 10 to 14 days), and 2) adverse effects likely to be related to the use of antibiotics. Secondary outcomes were: 1) abnormal tympanometry findings, 2) tympanic membrane perforation, 3) contralateral otitis (in unilateral cases), 4) AOM recurrences, 5) serious complications related to AOM and 6) long-term effects (including the number of parent-reported AOM symptom episodes, antibiotic prescriptions and health care utilisation as assessed at least one year after randomisation). We used the GRADE approach to rate the overall certainty of evidence for each outcome of interest. Antibiotics versus placebo We included 13 trials (3401 children and 3938 AOM episodes) from high-income countries, which we assessed at generally low risk of bias. Antibiotics do not reduce pain at 24 hours (risk ratio (RR) 0.89, 95% confidence interval (CI) 0.78 to 1.01; 5 trials, 1394 children; high-certainty evidence), or at four to seven days (RR 0.76, 95% CI 0.50 to 1.14; 7 trials, 1264 children), but result in almost a third fewer children having pain at two to three days (RR 0.71, 95% CI 0.58 to 0.88; number needed to treat for an additional beneficial outcome (NNTB) 20; 7 trials, 2320 children; high-certainty evidence), and likely result in two-thirds fewer having pain at 10 to 12 days (RR 0.33, 95% CI 0.17 to 0.66; NNTB 7; 1 trial, 278 children; moderate-certainty evidence). Antibiotics increase the risk of adverse events such as vomiting, diarrhoea or rash (RR 1.38, 95% CI 1.16 to 1.63; number needed to treat for an additional harmful outcome (NNTH) 14; 8 trials, 2107 children; high-certainty evidence). Antibiotics reduce the risk of children having abnormal tympanometry findings at two to four weeks (RR 0.83, 95% CI 0.72 to 0.96; NNTB 11; 7 trials, 2138 children), slightly reduce the risk of experiencing tympanic membrane perforations (RR 0.43, 95% CI 0.21 to 0.89; NNTB 33; 5 trials, 1075 children) and halve the risk of contralateral otitis episodes (RR 0.49, 95% CI 0.25 to 0.95; NNTB 11; 4 trials, 906 children). However, antibiotics do not reduce the risk of abnormal tympanometry findings at six to eight weeks (RR 0.89, 95% CI 0.70 to 1.13; 3 trials, 953 children) and at three months (RR 0.94, 95% CI 0.66 to 1.34; 3 trials, 809 children) or late AOM recurrences (RR 0.94, 95% CI 0.79 to 1.11; 6 trials, 2200 children). Severe complications were rare, and the evidence suggests that serious complications do not differ between children treated with either antibiotics or placebo. Immediate antibiotics versus expectant observation We included six trials (1556 children) from high-income countries. The evidence suggests that immediate antibiotics may result in a reduction of pain at two to three days (RR 0.53, 95% CI 0.35 to 0.79; NNTB 8; 1 trial, 396 children; low-certainty evidence), but probably do not reduce the risk of pain at three to seven days (RR 0.75, 95% CI 0.50 to 1.12; 4 trials, 959 children; moderate-certainty evidence), and may not reduce the risk of pain at 11 to 14 days (RR 0.91, 95% CI 0.75 to 1.10; 1 trial, 247 children; low-certainty evidence). Immediate antibiotics increase the risk of vomiting, diarrhoea or rash (RR 1.87, 95% CI 1.39 to 2.51; NNTH 10; 3 trials, 946 children; high-certainty evidence). Immediate antibiotics probably do not reduce the proportion of children with abnormal tympanometry findings at four weeks and evidence suggests that immediate antibiotics may not reduce the risk of tympanic membrane perforation and AOM recurrences. No serious complications occurred in either group. This review reveals that antibiotics probably have no effect on pain at 24 hours, a slight effect on pain in the days following and only a modest effect on the number of children with tympanic perforations, contralateral otitis episodes and abnormal tympanometry findings at two to four weeks compared with placebo in children with AOM. In high-income countries, most cases of AOM spontaneously remit without complications. The benefits of antibiotics must be weighed against the possible harms: for every 14 children treated with antibiotics, one child experienced an adverse event (such as vomiting, diarrhoea or rash) that would not have occurred if antibiotics were withheld. For most children with mild disease in high-income countries, an expectant observational approach seems justified. Therefore, clinical management should emphasise advice about adequate analgesia and the limited role for antibiotics.

Sections du résumé

BACKGROUND
Acute otitis media (AOM) is one of the most common diseases in childhood for which antibiotics are commonly prescribed; a systematic review reported a pooled prevalence of 85.6% in high-income countries. This is an update of a Cochrane Review first published in the Cochrane Library in 1997 and updated in 1999, 2005, 2009, 2013 and 2015.
OBJECTIVES
To assess the effects of antibiotics for children with AOM.
SEARCH METHODS
We searched CENTRAL, MEDLINE, Embase, Current Contents, CINAHL, LILACS and two trial registers. The date of the search was 14 February 2023.
SELECTION CRITERIA
We included randomised controlled trials comparing 1) antimicrobial drugs with placebo, and 2) immediate antibiotic treatment with expectant observation (including delayed antibiotic prescribing) in children with AOM.
DATA COLLECTION AND ANALYSIS
Two review authors independently screened trials for inclusion and extracted data using the standard methodological procedures recommended by Cochrane. Our primary outcomes were: 1) pain at various time points (24 hours, two to three days, four to seven days, 10 to 14 days), and 2) adverse effects likely to be related to the use of antibiotics. Secondary outcomes were: 1) abnormal tympanometry findings, 2) tympanic membrane perforation, 3) contralateral otitis (in unilateral cases), 4) AOM recurrences, 5) serious complications related to AOM and 6) long-term effects (including the number of parent-reported AOM symptom episodes, antibiotic prescriptions and health care utilisation as assessed at least one year after randomisation). We used the GRADE approach to rate the overall certainty of evidence for each outcome of interest.
MAIN RESULTS
Antibiotics versus placebo We included 13 trials (3401 children and 3938 AOM episodes) from high-income countries, which we assessed at generally low risk of bias. Antibiotics do not reduce pain at 24 hours (risk ratio (RR) 0.89, 95% confidence interval (CI) 0.78 to 1.01; 5 trials, 1394 children; high-certainty evidence), or at four to seven days (RR 0.76, 95% CI 0.50 to 1.14; 7 trials, 1264 children), but result in almost a third fewer children having pain at two to three days (RR 0.71, 95% CI 0.58 to 0.88; number needed to treat for an additional beneficial outcome (NNTB) 20; 7 trials, 2320 children; high-certainty evidence), and likely result in two-thirds fewer having pain at 10 to 12 days (RR 0.33, 95% CI 0.17 to 0.66; NNTB 7; 1 trial, 278 children; moderate-certainty evidence). Antibiotics increase the risk of adverse events such as vomiting, diarrhoea or rash (RR 1.38, 95% CI 1.16 to 1.63; number needed to treat for an additional harmful outcome (NNTH) 14; 8 trials, 2107 children; high-certainty evidence). Antibiotics reduce the risk of children having abnormal tympanometry findings at two to four weeks (RR 0.83, 95% CI 0.72 to 0.96; NNTB 11; 7 trials, 2138 children), slightly reduce the risk of experiencing tympanic membrane perforations (RR 0.43, 95% CI 0.21 to 0.89; NNTB 33; 5 trials, 1075 children) and halve the risk of contralateral otitis episodes (RR 0.49, 95% CI 0.25 to 0.95; NNTB 11; 4 trials, 906 children). However, antibiotics do not reduce the risk of abnormal tympanometry findings at six to eight weeks (RR 0.89, 95% CI 0.70 to 1.13; 3 trials, 953 children) and at three months (RR 0.94, 95% CI 0.66 to 1.34; 3 trials, 809 children) or late AOM recurrences (RR 0.94, 95% CI 0.79 to 1.11; 6 trials, 2200 children). Severe complications were rare, and the evidence suggests that serious complications do not differ between children treated with either antibiotics or placebo. Immediate antibiotics versus expectant observation We included six trials (1556 children) from high-income countries. The evidence suggests that immediate antibiotics may result in a reduction of pain at two to three days (RR 0.53, 95% CI 0.35 to 0.79; NNTB 8; 1 trial, 396 children; low-certainty evidence), but probably do not reduce the risk of pain at three to seven days (RR 0.75, 95% CI 0.50 to 1.12; 4 trials, 959 children; moderate-certainty evidence), and may not reduce the risk of pain at 11 to 14 days (RR 0.91, 95% CI 0.75 to 1.10; 1 trial, 247 children; low-certainty evidence). Immediate antibiotics increase the risk of vomiting, diarrhoea or rash (RR 1.87, 95% CI 1.39 to 2.51; NNTH 10; 3 trials, 946 children; high-certainty evidence). Immediate antibiotics probably do not reduce the proportion of children with abnormal tympanometry findings at four weeks and evidence suggests that immediate antibiotics may not reduce the risk of tympanic membrane perforation and AOM recurrences. No serious complications occurred in either group.
AUTHORS' CONCLUSIONS
This review reveals that antibiotics probably have no effect on pain at 24 hours, a slight effect on pain in the days following and only a modest effect on the number of children with tympanic perforations, contralateral otitis episodes and abnormal tympanometry findings at two to four weeks compared with placebo in children with AOM. In high-income countries, most cases of AOM spontaneously remit without complications. The benefits of antibiotics must be weighed against the possible harms: for every 14 children treated with antibiotics, one child experienced an adverse event (such as vomiting, diarrhoea or rash) that would not have occurred if antibiotics were withheld. For most children with mild disease in high-income countries, an expectant observational approach seems justified. Therefore, clinical management should emphasise advice about adequate analgesia and the limited role for antibiotics.

Identifiants

pubmed: 37965923
doi: 10.1002/14651858.CD000219.pub5
pmc: PMC10646935
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Systematic Review Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD000219

Commentaires et corrections

Type : UpdateOf

Informations de copyright

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Références

Health Technol Assess. 2021 Nov;25(67):1-76
pubmed: 34816795
Br Med J (Clin Res Ed). 1982 Apr 10;284(6322):1078-81
pubmed: 6802412
PLoS One. 2012;7(4):e36226
pubmed: 22558393
Pediatr Infect Dis J. 2013 Jul;32(7):745-7
pubmed: 23435311
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003539
pubmed: 16235325
BMJ. 2000 Feb 5;320(7231):350-4
pubmed: 10657332
N Engl J Med. 2011 Jan 13;364(2):116-26
pubmed: 21226577
J Pediatr. 1994 Mar;124(3):355-67
pubmed: 8120703
Br J Gen Pract. 2006 Mar;56(524):176-82
pubmed: 16536957
BMJ. 1994 Nov 12;309(6964):1286-91
pubmed: 7718048
BMJ. 1993 Apr 3;306(6882):895
pubmed: 8490414
Arch Otolaryngol Head Neck Surg. 2008 Feb;134(2):128-32
pubmed: 18283152
BMJ. 1991 Dec 7;303(6815):1450-2
pubmed: 1773154
Cochrane Database Syst Rev. 2000;(4):CD000219
pubmed: 11034677
Int J Pediatr. 2021 May 27;2021:5515467
pubmed: 34135974
Drugs. 2012 Oct 22;72(15):1991-7
pubmed: 23039319
J Pediatr. 1992 Jun;120(6):856-62
pubmed: 1534364
Cochrane Database Syst Rev. 2010 Sep 08;(9):CD001095
pubmed: 20824827
Arch Dis Child. 2022 Dec;107(12):1088-1094
pubmed: 35948405
Lancet. 2006 Oct 21;368(9545):1429-35
pubmed: 17055944
Acta Otolaryngol Suppl. 1954;113:1-79
pubmed: 13147804
Trials. 2016 Mar 03;17(1):119
pubmed: 26941013
Scand J Prim Health Care. 2007 Sep;25(3):166-71
pubmed: 17846935
CMAJ. 2005 Feb 1;172(3):335-41
pubmed: 15684116
JAMA Pediatr. 2014 Jul;168(7):635-41
pubmed: 24797294
Clin Otolaryngol Allied Sci. 1981 Feb;6(1):5-13
pubmed: 6791864
Cochrane Database Syst Rev. 2013 Apr 30;(4):CD004417
pubmed: 23633320
Pediatrics. 2003 May;111(5 Pt 1):1061-7
pubmed: 12728089
JAMA. 2003 Sep 24;290(12):1633-40
pubmed: 14506123
Pediatrics. 2005 Jun;115(6):1455-65
pubmed: 15930204
Pediatrics. 1991 Apr;87(4):466-74
pubmed: 2011422
JAMA. 2006 Sep 13;296(10):1235-41
pubmed: 16968847
Pediatrics. 2013 Mar;131(3):e964-99
pubmed: 23439909
Int J Infect Dis. 2011 Apr;15(4):e240-8
pubmed: 21269858
Br J Gen Pract. 2010 Feb;60(571):101-5
pubmed: 20132703
JAMA. 2010 Nov 17;304(19):2161-9
pubmed: 21081729
J Clin Epidemiol. 1999 Aug;52(8):725-30
pubmed: 10465316
Pediatrics. 2008 May;121(5):e1352-6
pubmed: 18450878
Pediatrics. 1995 Jul;96(1 Pt 1):126-31
pubmed: 7596700
Ann Otol Rhinol Laryngol Suppl. 1980 May-Jun;89(3 Pt 2):271-4
pubmed: 6778324
Antimicrob Agents Chemother. 2011 Nov;55(11):5022-6
pubmed: 21859932
Acta Otolaryngol. 2022 Jul-Aug;142(7-8):549-552
pubmed: 35980331
BMJ. 2001 Feb 10;322(7282):336-42
pubmed: 11159657
J Infect Dis. 1989 Jul;160(1):83-94
pubmed: 2732519
Clin Pediatr (Phila). 1972 Apr;11(4):205-14
pubmed: 4537206
Br Med J (Clin Res Ed). 1985 Apr 6;290(6474):1033-7
pubmed: 3921097
Am J Dis Child. 1968 May;115(5):542-51
pubmed: 4384577
Pediatr Infect Dis J. 2007 Jul;26(7):583-8
pubmed: 17596798
BMJ. 2009 Jun 30;338:b2525
pubmed: 19567910
Pediatr Infect Dis J. 2009 Jun;28(6):466-71
pubmed: 19504729
CMAJ. 2015 Jan 6;187(1):E21-E31
pubmed: 25404399
Pediatrics. 2003 May;111(5 Pt 1):e574-9
pubmed: 12728112
Pediatr Infect Dis J. 2012 Dec;31(12):1227-32
pubmed: 22760531
Pediatrics. 1990 Dec;86(6):848-55
pubmed: 2174535
Front Cell Infect Microbiol. 2021 Nov 01;11:768377
pubmed: 34790591
Clin Otolaryngol Allied Sci. 1994 Feb;19(1):35-40
pubmed: 8174299
Pediatr Infect Dis J. 2013 Aug;32(8):805-809
pubmed: 23860479
Lancet. 1981 Oct 24;2(8252):883-7
pubmed: 6117681
Lancet. 1989 Jul 15;2(8655):141-3
pubmed: 2567903
Can Med Assoc J. 1970 Feb 14;102(3):263-8
pubmed: 4190002
Cochrane Database Syst Rev. 2004;(1):CD000219
pubmed: 14973951
BMJ. 1991 Sep 7;303(6802):558-62
pubmed: 1912887
N Engl J Med. 2011 Jan 13;364(2):105-15
pubmed: 21226576

Auteurs

Roderick P Venekamp (RP)

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.

Sharon L Sanders (SL)

Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Australia.

Paul P Glasziou (PP)

Institute for Evidence-Based Healthcare, Bond University, Gold Coast, Australia.

Maroeska M Rovers (MM)

Department of Radiology and Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH